Education
About Us
Working with TipRanks
Follow Us
Ceribell, Inc. (CBLL)
:CBLL
CBLL Stock Chart & Stats
$21.99
-$0.15(-0.64%)
At close: 4:00 PM EST
$21.99
-$0.15(-0.64%)
Day’s Range― - ―
52-Week Range$10.01 - $28.23
Previous CloseN/A
Volume46.56K
Average Volume (3M)524.88K
Market Cap
$815.73M
Enterprise Value$275.71M
Total Cash (Recent Filing)$168.54M
Total Debt (Recent Filing)$21.34M
Price to Earnings (P/E)―
Beta0.80
Next Earnings
Mar 03, 2026EPS Estimate
-0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.37
Shares Outstanding37,095,690
10 Day Avg. Volume714,644
30 Day Avg. Volume524,885
Financial Highlights & Ratios
PEG Ratio1.93
Price to Book (P/B)4.22
Price to Sales (P/S)12.34
P/FCF Ratio-22.20
Enterprise Value/Market Cap0.34
Enterprise Value/Revenue3.33
Enterprise Value/Gross Profit3.78
Enterprise Value/Ebitda-5.61
Forecast
1Y Price Target
$25.17Price Target Upside14.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.51
Revenue Forecast (FY)$88.18M
Bulls Say, Bears Say
Bulls Say
Financial PerformanceQ3 revenue of $22.6M was up 31% and beat the $21.8M consensus.
Market ExpansionNeonatal and pediatric patients add another $400M to CBLL's existing $2B TAM.
Regulatory ApprovalsCeribell received FDA 510(k) clearance for Clarity for Neonates, the first and only seizure detection algorithm for pre-term neonates.
Bears Say
Market ShareCeribell is expected to retain nearly all its market share over this time period, dropping only incrementally from 77.5% share in 2024 to 72.3% share in 2027.
Rollout UncertaintyThe timing on the rollout of the delirium indication remains unclear, and more details will likely be provided at upcoming investor conferences.
Seasonal Launch ImpactCeribell does not launch new accounts in the final weeks of December, as holiday launches tend to be lower quality, so this clearance is not expected to materially impact 2025 numbers.
Ceribell, Inc. News
CBLL FAQ
What was Ceribell, Inc.’s price range in the past 12 months?
Ceribell, Inc. lowest stock price was $10.01 and its highest was $28.23 in the past 12 months.
What is Ceribell, Inc.’s market cap?
Ceribell, Inc.’s market cap is $815.73M.
When is Ceribell, Inc.’s upcoming earnings report date?
Ceribell, Inc.’s upcoming earnings report date is Mar 03, 2026 which is in 74 days.
How were Ceribell, Inc.’s earnings last quarter?
Ceribell, Inc. released its earnings results on Nov 04, 2025. The company reported -$0.37 earnings per share for the quarter, beating the consensus estimate of -$0.414 by $0.044.
Is Ceribell, Inc. overvalued?
According to Wall Street analysts Ceribell, Inc.’s price is currently Undervalued.
Does Ceribell, Inc. pay dividends?
Ceribell, Inc. does not currently pay dividends.
What is Ceribell, Inc.’s EPS estimate?
Ceribell, Inc.’s EPS estimate is -0.41.
How many shares outstanding does Ceribell, Inc. have?
Ceribell, Inc. has 37,095,690 shares outstanding.
What happened to Ceribell, Inc.’s price movement after its last earnings report?
Ceribell, Inc. reported an EPS of -$0.37 in its last earnings report, beating expectations of -$0.414. Following the earnings report the stock price went up 7.875%.
Which hedge fund is a major shareholder of Ceribell, Inc.?
Currently, no hedge funds are holding shares in CBLL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ceribell, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$25.17 (14.46% Upside)
$25.17 (14.46% Upside)
Blogger Sentiment
Bullish
CBLL Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 11.1%
Last 30 Days ▲ 15.0%
Last 30 Days ▲ 15.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-21.29%
12-Months-Change
Fundamentals
Return on Equity
-59.78%
Trailing 12-Months
Asset Growth
323.99%
Trailing 12-Months
Company Description
Ceribell, Inc.
Ceribell, Inc. (CBLL) is a healthcare technology company focused on transforming the management of epilepsy through its innovative seizure detection and monitoring solutions. Operating primarily in the medical device sector, Ceribell's core product is its FDA-cleared EEG monitoring system, which provides real-time data and insights for healthcare professionals to better manage and respond to seizures in patients. The company's mission is to improve patient outcomes and streamline the care process for individuals experiencing epilepsy and other seizure-related conditions.
CBLL Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Ceribell demonstrated strong revenue growth and notable expansion in accounts, particularly within the VA system. However, increased operating expenses and net loss were significant concerns. The company is actively managing tariff impacts with supply chain adjustments.View all CBLL earnings summariesCBLL Stock 12 Month Forecast
Average Price Target
$25.17
▲(14.46% Upside)
Technical Analysis
Ownership Overview
16.65% Insiders
21.44% Mutual Funds
32.08% Other Institutional Investors
22.95% Public Companies and
Individual Investors